Home Tools
Log in
Cart

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
Cat. No. Product name CAS No. Purity Chemical Structure
T4260 Capmatinib 2HCl 1197376-85-4 100%
INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highl...
T2208 Bacitracin Zinc 1405-89-6 63.98%
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
T5677 SAR125884 hydrochlorid (1116743-46-4(free base)) T5677 95%
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
T39507L Fosgonimeton acetate 97.05%
Fosgonimeton aceate is an agonist of hepatocyte growth factor (HGF).
T6095 JNJ-38877605 943540-75-8 97.15%
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
T3274 S49076 1265965-22-7 97.4%
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
T6907 NPS-1034 1221713-92-3 97.86%
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T7376 Dihexa 1401708-83-5 98%
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
T5656 (±)-Norcantharidin 29745-04-8 98%
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T6517 Golvatinib 928037-13-2 98%
Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-...
TQ0210 Savolitinib 1313725-88-0 98.03%
Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
T3550 X-376 1365267-27-1 98.29%
Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
T5467 SAR125844 1116743-46-4 98.39%
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
T2676 PF-04217903 956905-27-4 98.55%
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
T2680 NVP-BVU972 1185763-69-2 98.61%
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
T4332 C-Kit-IN-1 1225278-16-9 98.72%
DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
T1797 Cabozantinib S-malate 1140909-48-3 98.87%
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
T2282 RPI-1 269730-03-2 98.91%
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
T6260 AMG-208 1002304-34-8 99.12%
AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T13108 Pamufetinib 1190836-34-0 99.15%
TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...
Capmatinib 2HCl
T4260
INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highl...
Bacitracin Zinc
T2208
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
SAR125884 hydrochlorid (1116743-46-4(free base))
T5677
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
Fosgonimeton acetate
T39507L
Fosgonimeton aceate is an agonist of hepatocyte growth factor (HGF).
JNJ-38877605
T6095
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
S49076
T3274
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
NPS-1034
T6907
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
Dihexa
T7376
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
(±)-Norcantharidin
T5656
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Golvatinib
T6517
Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-...
Savolitinib
TQ0210
Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
X-376
T3550
Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
SAR125844
T5467
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
PF-04217903
T2676
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
NVP-BVU972
T2680
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
c-Kit-IN-1
T4332
DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
Cabozantinib S-malate
T1797
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
RPI-1
T2282
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
AMG-208
T6260
AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
Pamufetinib
T13108
TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...
1 2 3 4 5